Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth

• Published in: Cancer research (Chicago, Ill.) Vol. 76; no. 14_Supplement; p. 3262
• Main Authors: Mitsuhashi, Kaoru, Kimura, Takayuki, Hoshi, Taisuke, Tohyama, Osamu, Tai, Kenji, Ogo, Makoto, Matsuki, Masahiro, Yamaguchi, Atsumi, Ozawa, Yoichi, Adachi, Yusuke, Okamoto, Kiyoshi, Matsui, Junji, Funahashi, Yasuhiro
• Format: Journal Article
• Language: English
• Published: 15.07.2016

Abstract Lenvatinib mesilate (lenvatinib) is an orally available inhibitor for multiple receptor tyrosine kinases (RTKs) that selectively inhibits the kinase activities of VEGFR1, 2, and 3, in addition to other proangiogenic and oncogenic pathway-related RTKs including FGFR1, 2, 3, and 4; PDGFRα; KI...